Navigation Links
U.S. Biosimilars Market Worth $11Bn by 2020 - 22% CAGR Forecast for Global Biosimilar Industry in New Research Reports
Date:8/13/2015

CHICAGO, August 13, 2015 /PRNewswire/ --

The Global & USA Biosimilar Market Analysis to 2021 research report indicates a high market potential for biosimilars by 2019 when 50% of the biologics market is forecast to belong to off-patent drugs as there is tremendous interest by big pharma and generics companies in biosimilars industry.

Complete report on biosimilars market spread across 271 pages, profiling 90+ companies and supported with 134 tables and 89 figures is now available at http://www.reportsnreports.com/reports/411918-global-usa-biosimilar-market-analysis-to-2021-biobetters-erythropoietin-epo-human-growth-hormone-hgh-granulocyte-colony-stimulating-factor-g-csf.html .

The  U.S.,  Europe  and  Japan  are  spending  the  most  on biologics  and  therefore will  become  the  largest  biosimilar market hubs. Biosimilars generated revenues of $1.1 million in 2007 and gradually rose to $86.9 million in 2014. During this period, the market penetration of biosimilars in Europe and emerging markets was only about 8%. According to this new 2015 biosimilar market research, by 2019, 50% of the biologics market will belong to off-patent drugs, creating a high market potential for biosimilars. The top five biologics targeted most by biosimilar developers are Avastin, Enbrel, Herceptin, Humira and Rituxan, which together generate revenues of about $50 billion annually. In the E.U., where biosimilars are already competing with biologics, biosimilars are sold at a 30% discount compared to branded biologic drugs. In spite of the approval of 21 biosimilars in Europe, only 18% of the physicians are aware of these similar versions of biologics.

With the approval of the first biosimilar in the U.S in early 2015 and the expected patent expiration of 12 biologics by 2020, biosimilars are expected to competitively penetrate the biologic's market. Biosimilars have thus become a threat and opportunity for biotechnology and pharmaceutical sectors. Zarxio (Filgrastim, Sandoz) will be launched into the U.S. market in September 2015 and will compete with Neupogen (Amgen) within the US G-CSF market.

Biosimilars will account for 4% to 10% of the biologics market total by 2020, depending on the number of biosimilars launched in the U.S. The U.S. is the largest market for biologics and the biosimilars can achieve 10% of the global sales in 2020, only if the volume growth for biologics is achieved in the U.S. market.  The main players looking to penetrate the US biosimilar market are currently Amgen, Mylan, Pfizer, Sandoz and Hospira.

Companies profiled in this global and USA biosimilar market 2015 - 2021 research report include 3SBio Inc., Abzena, Actavis PLC, AET BioTech, Alvogen Inc., Amega Biotech, Amgen Inc., Anhui Anke Biotechnology (Group) Co., Ltd., Apotex Inc., Avesthagen Ltd., Baxter International Inc., Beijing Four Rings Biopharmaceutical Co., Ltd., Bharat Biotech International Ltd., Biocon Ltd., Biogen Inc., Bionovis SA, Biopartners GmbH, Biosidus S.A., BiotonSpólkaAkcyjna, Bioviz Technologies Pvt., Ltd., BioXpress Therapeutics SA, Biotechnol AS, Boehringer Ingelheim GmbH, Bolder BioTechnology Inc., Cadilla Pharmaceuticals Ltd, Celltrion Inc., Cerbios-Pharma S.A, Cipla Ltd., CJSC Biocad, Ckd Bio Corp., Claris Lifesciences Ltd., Coherus Biosciences Inc., CT Arzneimittel GmbH, Dawoong Pharmaceutical Co. Ltd., Dong-A Socio Holdings Co., Ltd., Dr. Reddy's Laboratories Ltd., Eli Lilly & Co., Emcure Pharmaceuticals Ltd., Epirus Biopharmaceuticals Inc., Finox AG, Fujifilm Diosynth Biotechnologies, Gan& Lee Pharmaceuticals Ltd., GeneScience Pharmaceuticals Co., Ltd., Genexine Co. Ltd., Gennova Biopharmaceuticals Ltd, Genor BioPharma Co., Ltd., Glenmark Pharmaceuticals Ltd., Glycotope GmbH, Green Cross Corp., HanAll BioPharma Co., Ltd., Hanwha Chemical Corp., Harvest Moon Pharmaceuticals USA Inc., Hetero Drugs Ltd., Hexal AG, Hospira Inc., Innovent Biologics Inc., Intas Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Kyowa Hakko Kirin Pharma Inc., LG Life Sciences Co., Ltd., Lupin Ltd., Mabion SA, mAbxience S.A., MacroGenics Inc., MediceArzneimittel Putter GmbH & Co. KG, Merck Serono, Merck & Co., Inc., MJ BiopharmPvt. Ltd., Mochida Pharmaceutical Co. Ltd., Momenta Pharmaceuticals Inc., Mycenax Biotech Inc., Mylan NV, Nippon Kayaku Co. Ltd., Oncobiologics Inc., Pfizer Inc., Pharma Praxis, PlantForm Corporation, Polpharma SA, Probiomed S.A. de C.V., ProtalixBioTherapeutics Inc., Ranbaxy Laboratories Ltd. (Sun Pharmaceutical Industries Ltd.), 1 Infimab, Ratiopharm GmbH, Reliance Life Sciences Pvt. Ltd., Samsung Bioepis Co., Ltd., Sandoz Inc., Shanghai CP Guojian Pharmaceutical Co., Ltd., Shantha Biotechnics Ltd., StadaArzneimittel AG, Synthon BV, Teva Pharmaceutical Industries Ltd., USV Ltd., Wockhardt Ltd., Xencor Inc. and Xiamen Amoytop Biotech Co., Ltd.

Order a copy of Global & USA BioSimilar Market Analysis to 2021; BioBetters, Erythropoietin (EPO), Human Growth Hormone (HGH), Granulocyte Colony-Stimulating Factor (G-CSF), Anti-Tumor Necrosis Factor (Anti-TNF), Monoclonal Antibodies (MAbs), Insulins, Interferons, Product Pipelines, Trends, Key Players, Regulations and Strategic Outlook research report at http://www.reportsnreports.com/Purchase.aspx?name=411918 .

On similar lines, another research titled Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Interferons, rHGH), Glycosylated (Monoclonal Antibodies, EPO), Peptides (Glucagon, Calcitonin)) & Application (Oncology, Blood Disorders) - Global Forecast to 2020 says global biosimilars market is estimated to be worth $2.29 billion in 2015, and is poised to grow at a CAGR of 22.1% during the forecast period. The recombinant glycosylated proteins segment is expected to witness the highest growth rate owing to the increased demand for monoclonal antibodies in the treatment of cancer (oncology), autoimmune disorders, blood disorders, and infectious diseases. On the other hand, the recombinant non-glycosylated proteins segment accounts for the largest share of the market in 2015. The insulin segment is poised to be the fastest-growing segment of the recombinant non-glycosylated proteins market, growing at a CAGR of 28.1% from 2015 to 2020. Growth in this insulin market is attributed to the rising incidences of diabetes; ongoing patent expirations of biologic drugs such as Lantus, Humalog, and Novorapid; and the cost effectiveness of insulin. Geographically, Europe is expected to account for the largest share of the global biosimilars market in 2015 followed by Asia-Pacific. Companies like Hospira, Inc., Roche Diagnostics (A Division of F. Hoffmann-La Roche Ltd.), Sandoz International GmbH (A Division of Novartis International Ag), Teva Pharmaceutical Industries Ltd., Amgen, Biocon Ltd., Dr. Reddy's Laboratories, Celltrion, Inc., Mylan, Inc. and Merck KGAA are profiled in this 162 pages biosimilars market research available at http://www.reportsnreports.com/reports/270786-biosimilars-market-product-recombinant-non-glycosylated-proteins-insulin-filgrastim-somatropin-glycosylated-monoclonal-antibodies-erythropoietin-peptides-glucagon-calcitonin-application-oncology-blood-disorders-global-forecast-to-2018.html .

The third research titled BIOSIMILARS - Regulatory Framework and Pipeline Analysis provides information on regulatory overview, biosimilar guidelines, regulatory framework for biosimilars, and market outlook for: Europe, USA, India, South Korea, Japan and China. Covering market dynamics (trends, drivers and barriers), WHO guidance for biosimilars, key players and pipeline analysis as well as an overview by stage of development / molecule / therapy area / indication and late stage / phase - II / phase I pipeline biosimilars, this 94 pages research report is available at http://www.reportsnreports.com/reports/403699-biosimilars-regulatory-framework-and-pipeline-analysis.html .

Explore more reports on biotechnology market as well as pharmaceuticals industry at http://www.reportsnreports.com/market-research/pharmaceuticals/ .

About Us:  

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Connect With Us on:  

Facebook: https://www.facebook.com/pages/ReportsnReports/191441427571689

LinkedIn: http://www.linkedin.com/company/reportsnreports

Twitter: https://twitter.com/marketsreports

G+ / Google Plus: https://plus.google.com/111656568937629536321/posts

Pinterest: http://www.pinterest.com/comeonseo/reportsnreports/

RSS/Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml

Contact:
Ritesh Tiwari
1 South Dearborn Street,
21st Floor, Chicago,
IIIinois 60603, USA.
+ 1 888 391 5441
sales@reportsandreports.com



'/>"/>
SOURCE ReportsnReports
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. BIOSIMILARS Market Study - Regulatory Framework and Pipeline Analysis 2015-2020: Market Expected to Reach $55 Billion
2. Global Biosimilars Market Forecasts 2015-2020 - Analysis of the $2.2 Billion Industry
3. The Biosimilars Council Announces Chairman of the Board of Directors, Officers
4. Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2015-2025
5. Survey Of Rheumatologists Nationwide Regarding Biosimilars Highlights Need For More Robust FDA Standards
6. Hospira, Alliance for Health Reform Bring Food and Drug Administration, Industry Experts Together to Discuss the Future of Biosimilars in the United States
7. Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation
8. Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation
9. GPhA Launches Biosimilars Council, New Industry Group Will Educate and Advocate for Patient Access to Safe, Affordable Lifesaving Medicines
10. Canadian Generic Pharmaceutical Association (CGPA) Establishes First Voice for Biosimilars in Canada
11. Amgen To Present At The Goldman Sachs Key Debates In Biosimilars Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)...  True Health, a leader in integrated diagnostics ... National Breast Cancer Awareness month to educate doctors ... Research recently published in ... than 10 million American women are at significant ... BRCA2 and have not had testing. These mutations can ...
(Date:10/5/2017)... ROSEMONT, Ill. , Oct. 5, 2017 /PRNewswire-USNewswire/ ... American Association of Oral and Maxillofacial Surgeons (AAOMS) ... than opioids – to be used as a ... post-surgical pain. ... relationship, the AAOMS White Paper "Opioid Prescribing: Acute ...
(Date:10/2/2017)... Oct. 2, 2017  Eli Lilly and Company (NYSE: ... for the third quarter of 2017 on Tuesday, October ... on that day with the investment community and media ... The conference call will begin at 9 a.m. Eastern ... a live webcast of the conference call through a ...
Breaking Medicine Technology:
(Date:10/13/2017)... York, NY (PRWEB) , ... October 13, 2017 , ... ... influential people in business to advocate for action towards gender equality at their inaugural ... views from around the globe, and reached a social audience of over 3 million. ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “The Journey: From ... every danger possible to save lost souls in the Philippines. “The Journey: From the ... is a dedicated teacher of the Bible. She has taught all ages and currently ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, the Los ... article to the newly revamped Cosmetic Town journal section, featuring articles ... procedure known as Follicular Unit Extraction (FUE). , Dr. Mohebi says ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations ... literacy software tool, and the Cancer Patient Education Network (CPEN), an independent professional ... announce a new strategic alliance. , As CPEN’s strategic partner, HLI will ...
Breaking Medicine News(10 mins):